After Barclays and Stifel Nicolaus gave Becton Dickinson (NYSE: BDX) a Buy rating last month, the company received another Buy, this time from Wells Fargo. Analyst Larry Biegelsen maintained a Buy rating on Becton Dickinson yesterday. The company’s shares closed last Monday at $258.48, close to its 52-week high of $265.87.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 14.8% and a 68.2% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Merit Medical Systems, and Shockwave Medical Inc.
Currently, the analyst consensus on Becton Dickinson is a Strong Buy with an average price target of $272.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $265.87 and a one-year low of $208.62. Currently, Becton Dickinson has an average volume of 1.02M.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
